These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 10363988

  • 1. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
    Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, Veglia F, Corti A, Casorati G, Dellabona P.
    Cancer Res; 1999 Jun 01; 59(11):2650-6. PubMed ID: 10363988
    [Abstract] [Full Text] [Related]

  • 2. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G.
    Eur J Immunol; 1996 Aug 01; 26(8):1851-9. PubMed ID: 8765031
    [Abstract] [Full Text] [Related]

  • 3. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T, Martuza RL, Dallman MJ, Rabkin SD.
    Cancer Res; 2001 Jan 01; 61(1):153-61. PubMed ID: 11196154
    [Abstract] [Full Text] [Related]

  • 4. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA, DeBenedette MA, Watts TH, Berinstein NL.
    J Immunol; 1999 Apr 15; 162(8):5003-10. PubMed ID: 10202049
    [Abstract] [Full Text] [Related]

  • 5. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X, Wong MK, Yi H, Watkins S, Laird AD, Wolf SF, Gorelik E.
    Cancer Res; 2002 Oct 15; 62(20):5727-35. PubMed ID: 12384531
    [Abstract] [Full Text] [Related]

  • 6. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
    Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S.
    J Immunol; 1996 May 15; 156(10):3821-7. PubMed ID: 8621919
    [Abstract] [Full Text] [Related]

  • 7. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
    Mokyr MB, Kalinichenko TV, Gorelik L, Bluestone JA.
    J Immunol; 1998 Feb 15; 160(4):1866-74. PubMed ID: 9469448
    [Abstract] [Full Text] [Related]

  • 8. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 9. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
    Cavallo F, Martin-Fontecha A, Bellone M, Heltai S, Gatti E, Tornaghi P, Freschi M, Forni G, Dellabona P, Casorati G.
    Eur J Immunol; 1995 May 15; 25(5):1154-62. PubMed ID: 7539748
    [Abstract] [Full Text] [Related]

  • 10. Immunogene therapy against mouse leukemia using B7 molecules.
    Takahashi T, Hirano N, Takahashi T, Chiba S, Yazaki Y, Hirai H.
    Cancer Gene Ther; 2000 Jan 15; 7(1):144-50. PubMed ID: 10678367
    [Abstract] [Full Text] [Related]

  • 11. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.
    Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD.
    J Immunol; 1996 Feb 01; 156(3):1126-31. PubMed ID: 8557988
    [Abstract] [Full Text] [Related]

  • 12. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS, Lee BC, Kim E, Cho D, Cohen EP.
    Vaccine; 2008 Nov 05; 26(47):5928-34. PubMed ID: 18793691
    [Abstract] [Full Text] [Related]

  • 13. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
    La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB.
    J Immunol; 1998 Dec 15; 161(12):6552-8. PubMed ID: 9862681
    [Abstract] [Full Text] [Related]

  • 14. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS, Chung SW, Kim SH, Kang BY, Hwang SY, Lee JW.
    Cancer Gene Ther; 2000 Jun 15; 7(6):861-9. PubMed ID: 10880016
    [Abstract] [Full Text] [Related]

  • 15. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL.
    Cancer Res; 1995 Nov 01; 55(21):4980-7. PubMed ID: 7585539
    [Abstract] [Full Text] [Related]

  • 16. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo.
    Sigal LJ, Reiser H, Rock KL.
    J Immunol; 1998 Sep 15; 161(6):2740-5. PubMed ID: 9743331
    [Abstract] [Full Text] [Related]

  • 17. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
    Hodge JW, Abrams S, Schlom J, Kantor JA.
    Cancer Res; 1994 Nov 01; 54(21):5552-5. PubMed ID: 7522961
    [Abstract] [Full Text] [Related]

  • 18. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW.
    Cancer Res; 2001 Mar 01; 61(5):1948-56. PubMed ID: 11280751
    [Abstract] [Full Text] [Related]

  • 19. Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells.
    Zheng G, Liu S, Wang P, Xu Y, Chen A.
    Cancer Res; 2006 Jul 01; 66(13):6793-9. PubMed ID: 16818656
    [Abstract] [Full Text] [Related]

  • 20. Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules.
    Liu Y, Wang H, Zhao J, Ma J, Wei L, Wu S, Xie T, Shen F, Trojan J, Habib N, Anthony DD, Wu M, Guo Y.
    Cancer Gene Ther; 2000 Mar 01; 7(3):456-65. PubMed ID: 10766352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.